SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as community members discuss its recent listing and availability on Phantom Wallet. The Solana-based token is being touted for its potential gains, with many highlighting its strong momentum and comparing it to other meme coins. Some users note its relative stability amidst broader market volatility.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending as investors react to President Trump's comments on trade relations with China, which have injected volatility into the market. Community members are actively discussing potential market impacts and the effectiveness of tariff strategies. The ETF is caught in broader market uncertainty amidst concerns about global economic tensions.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending amid discussions about market conditions and potential corrections, influenced by factors like tariff impacts, government shutdowns, and AI developments. Community members are actively debating the ETF's performance relative to other investment options and reacting to news impacting its diverse holdings, such as political events and economic data. Conversations also include discussions around diversification, portfolio strategy, and individual stock picks versus broader market ETFs.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as the community rallies behind it as the top memecoin on Bitcoin, emphasizing its fair launch and strong community-driven nature. Discussions highlight its potential to outperform other memecoins and its unique position within the Bitcoin ecosystem. Community members are actively promoting its listing on major exchanges and emphasizing its potential for significant growth.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid anticipation for its Super App release and upcoming listings on major exchanges like Coinbase and Binance. The community is bullish, drawing comparisons to XRP and highlighting potential NBA and NHL sponsorships. Discussions also involve the project's utility in payroll and staking rewards through Uphold.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around a potential options play and broader market reactions to political news. Community members are expressing varied opinions on the stock, with some focusing on the company's fundamentals, while others discuss its relationship to political events and figures. The stock's movements are being closely watched within the context of ongoing political and economic developments.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as investors assess the impact of a recent FDA safety notice regarding hypersensitivity reactions to specific lots of intravenous immune globulin, including some ADMA products; the community is weighing the potential financial impact of voluntary withdrawals and discussing whether a recent stock sale by the CEO is related to the news. Some see the dip as a buying opportunity given the company's growth and buyback program, while others express concern about potential revenue impacts and are awaiting further updates from management.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amidst discussions on tariffs, CPI, and their potential impact, with community members debating whether previous losses have been recovered adequately. Chatter includes short interest, potential revenue beats, and forward-looking market valuation. The stock is also reacting to broader market forces like gold price fluctuations and sector-specific news from competitors.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF (BTC) is trending amid broader cryptocurrency market discussions, particularly around Solana-based tokens. Community chatter highlights enthusiasm for Solana projects, with the stock also influenced by Bitcoin's overall market movements and potential integration with AI technologies.

GE Vernova, Inc. is a electric power industry. Its products and services generate, transfer, orchestrate, convert, and store electricity. The firm operates through the following segments: Power, Wind and Electrification. The Power segment includes design, manufacture, and servicing of gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. The Electrification segment includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The Company was founded November 09, 2021 and is headquartered in Cambridge, Massachusetts.

GE Vernova Inc.

GE Vernova is trending due to its central role in meeting the increasing power demands of AI data centers, with discussions focusing on its gas turbine and SMR technologies. Community members are actively discussing recent earnings and analyst target price updates, with some anticipating further upside potential. The stock's high valuation and potential overbought conditions are also being debated.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.

Celldex Therapeutics shares slipped in after-hours trading&nbsp;on&nbsp;Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis (EoE).The stock closed down 1.9% at $24.02 on Tuesday and slid another 14.2% to $20.62 in after-hours trading following its Phase 2 EoE update.The decision to pull the plug on the&nbsp;EoE candidate came after&nbsp;the Phase 2 trial hit its primary goal by reducing mast cells in the esophagus, but the depletion failed to bring meaningful improvements for patients.No differences were observed between barzolvolimab and placebo in dysphagia symptom scores, endoscopic assessment of inflammation and fibrosis, or histological reduction in eosinophil infiltration.&nbsp;Celldex said the results provide direct evidence that mast cells are not a primary driver of the disease.The study confirmed barzolvolimab’s favorable safety and tolerability profile at the dosing regimen that was tested, consistent with prior studies where dosing was less frequent.&nbsp;“While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options,” said Chief Executive Officer Anthony Marucci.Marucci added that Celldex remains committed to barzolvolimab’s broader pipeline, with enrollment ongoing in four studies: two Phase 3 trials in chronic spontaneous urticaria and two Phase 2 trials in atopic dermatitis and prurigo nodularis.&nbsp;The company is also finalizing plans to initiate a Phase 3 program in inducible urticaria, covering cold urticaria and symptomatic dermographism.On Stocktwits, retail sentiment for Celldex was ‘bullish’ amid ‘high’ message volume.One user focused on Celldex’s pivot toward chronic spontaneous urticaria (CSU), saying investors are primarily betting on the Phase 3 program after strong Phase 2 data, which they described as better than the current standard of care.&nbsp;They noted that CSU represents a much larger commercial opportunity, with market leader Xolair bringing in more than $4 billion in revenue in 2024.<stembedurl>https://stocktwits.com/TheGunnerAB/message/625855252</stembedurl>Another user suggested the pullback could be a buying opportunity, calling it a good time to add to positions in Celldex.<stembedurl>https://stocktwits.com/StockHunter75/message/625842884</stembedurl><a href="https://stocktwits.com/symbol/CLDX">Celldex’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celldex Therapeutics (CLDX) shares slipped in after-hours trading on Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis. (Photo credit: Getty Images)

Why Are Celldex Shares Tumbling After Hours?

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 

Equity

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail investor chatter around Celldex Therapeutics spiked on Sunday following new Phase 2 data showing barzolvolimab provided “profound long-term” relief from angioedema in patients with chronic spontaneous urticaria (CSU).Celldex shares closed 4.5% higher at $21.26 on Friday.The company presented updated 52-week results at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress in Glasgow, showing that 77% of patients on barzolvolimab were angioedema-free at Week 52.&nbsp;The antibody therapy also showed up to 87% of patients reported “clinically meaningful” improvements in angioedema activity scores (AAS7).Barzolvolimab targets KIT, a receptor tyrosine kinase involved in mast cell regulation.&nbsp;In CSU, mast cells drive persistent inflammation and swelling even after standard antihistamine therapy fails.Patients with severe CSU and angioedema frequently endure disfigurement and debilitating pain, said Diane C. Young, MD, Chief Medical Officer at Celldex.&nbsp;Additional data showed an 86% mean reduction in angioedema activity in the 150 mg group and 82% in the 300 mg every-8-weeks group.&nbsp;Patients remained angioedema-free for 72% of the year-long treatment period.Retail sentiment on platforms such as Stocktwits and Reddit turned sharply bullish over the weekend, with several users highlighting the durability of symptom control and potential differentiation from existing CSU treatments like Novartis’ Xolair.The 208-patient Phase 2 trial had previously met all primary and secondary endpoints at 12 weeks.&nbsp;A global Phase 3 program is underway, targeting antihistamine-refractory CSU patients, including those previously treated with biologics.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.Celldex stock has declined 17.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock

Latest Ratings for CLDX
 DateFirmActionFromTo Sep 2021JefferiesInitiates Coverage OnBuy Sep 2021HC Wainwright & Co.MaintainsBuy Sep 2021SVB LeerinkInitiates Coverage OnOutperform
 View More...

Analyst Expectations For Celldex Therapeutics's Future

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics

7 Analysts Have This To Say About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLDX News

CLDXCelldex Therapeutics Inc.